WCLC 2025 - Posters & ePosters-P3.18.58 Trastuzumab Deruxtecan + Pembrolizumab as First-Line Treatment in HER2-Overexpressing, PD-L1 Tps <50% NSCLC (DESTINY-Lung06)

P3.18.58 Trastuzumab Deruxtecan + Pembrolizumab as First-Line Treatment in HER2-Overexpressing, PD-L1 Tps <50% NSCLC (DESTINY-Lung06)

Asset Subtitle

William William Jr.

Meta Tag

Speaker William William Jr.

Topic Clinical Trials in Progress